LQDA VS ABBV Stock Comparison

PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatilityDividend
PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatilityDividend

Performance

LQDA
100/100

LQDA returned 32.09% in the last 12 months. Based on SPY's performance of -13.52%, its performance is above average giving it a score of 100 of 100.

ABBV
100/100

ABBV returned -4.80% in the last 12 months. Based on SPY's performance of -20.59%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

LQDA
88/100

4 analysts offer 12-month price targets for LQDA. Together, they have an average target of 12, the most optimistic target put LQDA at 17 within 12-months and the most pessimistic has LQDA at 3.

ABBV
68/100

20 analysts offer 12-month price targets for ABBV. Together, they have an average target of 158.73, the most optimistic target put ABBV at 200 within 12-months and the most pessimistic has ABBV at 127.

Sentiment

LQDA
68/100

LQDA had a bullish sentiment score of 67.78% across Twitter and StockTwits over the last 12 months. It had an average of 2.48 posts, 3.23 comments, and 3.61 likes per day.

ABBV
71/100

ABBV had a bullish sentiment score of 71.15% across Twitter and StockTwits over the last 12 months. It had an average of 130.21 posts, 1,504.50 comments, and 7,664.76 likes per day.

Technicals

LQDA
29/100

LQDA receives a 28 of 100 based on 14 indicators. 3 are bullish, 9 are bearish.

ABBV
11/100

ABBV receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

LQDA
10/100

LQDA has missed earnings 11 times in the last 20 quarters.

ABBV
100/100

ABBV has missed earnings 0 times in the last 20 quarters.

Profit

LQDA
10/100

Out of the last 20 quarters, LQDA has had 0 profitable quarters and has increased their profits year over year on 0 of them.

ABBV
80/100

Out of the last 20 quarters, ABBV has had 18 profitable quarters and has increased their profits year over year on 11 of them.

Volatility

LQDA
48/100

LQDA has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

ABBV
47/100

ABBV has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

Dividend

LQDA

"Dividend" not found for LQDA

ABBV
100/100

ABBV's most recent dividend was $0.97 per share, based on a share price of $138.93. It was a payout ratio of 53.19% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

Liquidia Corporation Common Stock Summary

Nasdaq / LQDA
Healthcare
Biotechnology
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

ABBVIE INC. Summary

New York Stock Exchange / ABBV
Healthcare
Drug Manufacturers - General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.